Frequently Asked Questions

We design, launch, and scale your global expansion—owning regulatory strategy, distributor governance, commercial execution, and post-launch performance across every market. Class II/III devices, SaMD, and AI/ML-enabled products across the U.S., Europe, LATAM, APAC, GCC, and emerging markets. This isn't consulting. We take the wheel. From regulatory clearance to revenue generation, we're accountable for outcomes.

Our ideal clients include: ·      C-suite executives at medical device and SaMD companies preparing for global scale ·      Growth-stage MedTech companies expanding beyond early markets without building in-house international teams ·      PE/VC investors building multi-asset, multi-region MedTech portfolios ·      Distribution company owners and executives seeking to strengthen commercial infrastructure ·      Healthcare investors evaluating or scaling MedTech assets across regulated markets If regulatory complexity, AI/ML components, and multi-region growth are central to your strategy or investment thesis, we're built for you.

We address the hidden failure modes that quietly erode value in global MedTech expansion: ·      Fragmented execution — Regulatory, distributor selection, and clinical adoption treated as separate workstreams when they're actually one coupled system ·      Underperforming distributors — Partners chosen on relationships rather than audited capability, lacking real performance leverage ·      Regulatory bottlenecks — Timelines assumed instead of modeled, creating costly surprises and delays ·      Stalled adoption — Products that launch but never scale because clinical champions aren't in place ·      Unclear market priorities — Companies attempting to enter multiple countries simultaneously without data-driven sequencing ·      Investor skepticism — Boards seeing delayed approvals, capital burned across geographies, and missed inflection points We clarify which markets to enter, in what sequence, through which regulatory pathways and commercial channels—and how those choices affect valuation, revenue timing, and risk across your portfolio.

We are operators, not advisors. We've owned P&L, carried regulatory risk, and managed launches across 27 countries. Consultants provide recommendations. We own execution and outcomes. Table 1: Comparative positioning of Distributor Principles We connect regulatory strategy, clinical plans, reimbursement, and channel execution into one operating blueprint—not isolated workstreams.

We focus exclusively on regulated medical technologies: Class II/III devices, IVDs, SaMD, AI/ML-enabled products, and hardware-software-data combinations. Our expertise spans FDA, EU-MDR/IVDR, UK MHRA, TGA, and APAC/LATAM frameworks—including AI/ML-specific requirements like PCCPs, lifecycle management, data governance, and algorithm transparency.

The GlobalGate System™ is our proprietary operating system, a repeatable, codified playbook that integrates market feasibility, regulatory pathway execution, distributor governance, clinical advocacy, and investor-ready reporting under a single point of accountability. The 4 Phases: ·      ASSESS (markets, strategy) ·      STRUCTURE (contracts, regulatory, infrastructure) ·      LAUNCH (execute, capture, deliver) ·      OPTIMIZE (safeguard, maximize, control, expand) This isn't a framework, it's an executable playbook with defined owners, KPIs, and governance checkpoints at every stage. Each reuse cycle reduces delivery cost without reducing engagement value, creating structural margin expansion as we scale.

We support clients across all major regulated markets and high-growth emerging regions: ·      United States — FDA pathways (510(k), De Novo, PMA) ·      Europe — EU-MDR/IVDR compliance, CE marking ·      United Kingdom — MHRA post-Brexit pathways, UKCA marking ·      Latin America (LATAM) — Including Brazil (ANVISA), Mexico (COFEPRIS), and key markets ·      Asia-Pacific (APAC) — Australia (TGA), Singapore (HSA), Japan (PMDA), China (NMPA), and others ·      GCC (Gulf Cooperation Council) — Saudi Arabia (SFDA), UAE, and regional markets We blend global standards with local nuance through our coordinated team and in-market specialists. Our founder has built international divisions in 27 countries across all regions, delivering 134% average year-over-year growth for five consecutive years.